GeNeuro SA's latest marketcap:
As of 07/28/2025, GeNeuro SA's market capitalization has reached $952,201.05. According to our data, GeNeuro SA is the 48028th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 952,201.05 |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -17,327,669.4 |
| Shares Out | 29.6 M |
| EPS (ttm) | -0.7 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/19/2025 |
GeNeuro SA's yearly market capitalization.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/28/2025 | €810,936 | $952,201.05 | -64.96% | 48028 |
| 12/31/2024 | €2.31 M | $2.4 M | -91.46% | 42859 |
| 12/29/2023 | €27.1 M | $29.91 M | -27.36% | 31189 |
| 12/30/2022 | €37.3 M | $39.92 M | -52.68% | 28408 |
| 12/31/2021 | €78.83 M | $89.59 M | 37.49% | 23816 |
| 12/31/2020 | €57.33 M | $70.03 M | 6.29% | 22742 |
| 12/31/2019 | €53.94 M | $60.48 M | 7.49% | 20855 |
| 12/31/2018 | €50.18 M | $57.54 M | -39.79% | 20218 |
| 12/29/2017 | €83.35 M | $99.97 M | -44.01% | 17992 |
| 12/30/2016 | €148.85 M | $156.54 M | 13849 |
Company Profile
About GeNeuro SA
GeNeuro SA is a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative and autoimmune diseases. Founded in 2006 and headquartered in Plan-les-Ouates, Switzerland, the company leverages cutting-edge research to address unmet medical needs.
Key Therapeutic Candidates
- Temelimab: A monoclonal antibody targeting pathogenic proteins of the HERV-W family, currently completed Phase II clinical trials.
- GNC-501: In Phase 2 clinical trials for post-COVID patients with persistent neuropsychiatric syndromes.
- GNK301: A preclinical development program for sporadic amyotrophic lateral sclerosis (ALS).
Strategic Collaborations
GeNeuro SA has established key partnerships to advance its research and development efforts:
- Collaboration with The National Institute of Neurological Disorders and Strokes to develop an antibody program targeting pHERV-K Env.
- Partnership with FondaMental Foundation for diagnostic and therapeutic solutions for Post-COVID neuropsychiatric syndromes.
- Research agreement with Northwestern University to study human endogenous retrovirus W envelope protein (W-ENV) in long-haul COVID patients.
- Collaboration with the US National Institute of Health to explore pHERV-K (K-ENV) as a therapeutic target for ALS.
Frequently Asked Questions
-
What is GeNeuro SA's (EPA-GNRO) current market cap?As of 07/28/2025, GeNeuro SA (including the parent company, if applicable) has an estimated market capitalization of $952,201.05 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does GeNeuro SA (EPA-GNRO) rank globally by market cap?GeNeuro SA global market capitalization ranking is approximately 48028 as of 07/28/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.